The L’Oréal Group has announced a partnership with Abolis Biotechnologies, a biotechnology company, and Evonik, a world leader in specialty chemicals, to deploy the next generation of innovative and sustainable bio-based ingredients for beauty products and beyond.
The agreement is bolstered by L’Oréal and Evonik’s respective minority investments in Abolis.
Abolis is a French biotech firm with unique expertise in tailor-made industrial solutions based on microorganisms for a wide range of industries including cosmetics, healthcare and food.
The investment will allow Abolis to expand its capabilities in the development of microbe-powered solutions that help industries transition to more sustainable business models. It marks a new, strategic phase in the L’Oréal-Abolis collaboration, which began in 2019 and led to an extended lab set-up in 2022.
“We are proud to invest in Abolis and expand our collaboration, working together as a tight ecosystem alongside our historical partner, Evonik,” said Barbara Lavernos, Deputy Chief Executive Officer in charge of Research, Innovation and Technology, L’Oréal Groupe. “By mobilizing our respective companies’ research, innovation and manufacturing capabilities and expertise, we are building an end-to-end value chain that we believe has tremendous potential to be a game-changer in bio-based ingredients for beauty.”
